Orbofiban is an orally active platelet GPIIb/IIIa antagonist that inhibits platelet aggregation.

Triperiden is an inhibitor of influenza virus multiplication. Triperiden targets the haemagglutinin of fowl plague virus (FPV) for antiviral activity and acts by inhibiting the conformational change in the haemagglutinin at acid pH. Triperiden is also anticholinergic anti-parkinsonism drug.

Lubeluzole is a neuroprotective anti-ischemic compound. Lubeluzole, but not its (-)-R-isomer, protects against sensorimotor deficits provoked by photochemical stroke in rats. Lubeluzole inhibited glutamate-stimulated guanosine 3',5'-cyclic monophosphate production with an IC50 of 37 nM. Lubeluzole also has the potential for developing a novel class of antibacterial adjuvants endowed with spasmolytic activity.

4-Sulfo-N-(4-aminobenzyl)-1,8-naphthalimide potassium is an inactive 1,8-Naphthalimide derivative. 4-Sulfo-N-(4-aminobenzyl)-1,8-naphthalimide potassium can be used as a negative control for the clathrin inhibitor 3-Sulfo-N-benzyl-1,8-naphthalimide, potassium salt.

Lexipafant is a platelet-activating factor (PAF) antagonist that inhibits the inflammatory response and is used in the treatment of acute pancreatitis.

2-nonyl-3-hydroxy-4-Quinolone (C9-PQS) is a quinolone compound produced by P. aeruginosa and other related bacterias. 2-nonyl-3-hydroxy-4-Quinolone is a quorum sensing (QS) signal molecule that controls the expression of many virulence genes as a function of cell population density.

Navamepent is an analog of naturally occurring resolvin E1 (a major dietary omega-3 polyunsaturated fatty-acid metabolite) with potent anti-inflammatory and cell survival benefits. Navamepent is highly effective against dry eye and goblet cell loss thereby accelerating tear production. Also, Navamepent can reduce corneal inflammation, epithelial damage, and accelerate corneal tissue repair. In addition, Navamepent can inhibit the release of several key proinflammatory mediators from corneal epithelial cells.

Linaprazan glurate inhibits exogenously or endogenously stimulated gastric acid secretion. Linaprazan glurate exhibits several advantageous properties, such as fast onset, high in vivo potency and/or long duration of action. Linaprazan glurate is useful in the research of gastrointestinal inflammatory diseases and peptic ulcer diseases (extracted from patent WO2010063876A1).

MK-5204 is an orally active β-1,3-glucan synthesis inhibitor.

Dipentamethylenethiuram Tetrasulfide is a material for constructing rubber (extracted from patent CN112876756A).

XTT (sodium) is used to assess cell viability as a function of redox potential. Actively respiring cells convert the water-soluble XTT to a water-soluble, orange colored formazan product.

HbF inducer-1 is an orally bioavailable fetal hemoglobin inducer.

OXS007417 induces differentiation of acute myeloid leukemia cells (EC50 = 48 nM) in vitro and shows antitumor effects in vivo.

Sucistil is an active compound. hemoglobin sucistil (bovine) is an oxygen carrier.

ART615 is the related isomer of ART558. ART615 elicits <10% Polθ inhibition at 12 µM, thus serving as a control for ART558 (IC50=7.9 nM).

Debotansine is a immunomodulator and antineoplastic.

O-GlcNAcase-IN-1 is a potent and novel OGA inhibitor with an IC50 value of 46 nM.

Retezorogant is a retinoid-related orphan receptor γ (RORγ) antagonist, extracted from patent WO2016093342 A1.

10-Nitrolinoleic acid is a potent peroxisome proliferator-activated receptor γ (PPARγ) agonist. 10-Nitrolinoleic acid competes with [3H]Rosiglitazone for binding to PPAR-γ, with an IC50 of 0.22 μM.

Ragaglitazar is a PPARα and PPARγ agonist with potent lipid-lowering and insulin-sensitizing efficacy in animal models. Ragaglitazar improves glycemic control and lipid profile in type 2 diabetic.

KRP-297 is a PPARα and PPARγ agonist potentially for the treatment of type 2 diabetes and dyslipidemia. KRP-297 restores reduced lipid oxidation, and inhibits of enhanced lipogenesis and triglyceride accumulation in the liver.

Farglitazar is a PPARγ agonist that has significant therapeutic benefits such as glycemic control in type 2 diabetic patients.

Rivoglitazone is a thiazolidinedione-derivative PPARγ agonist for the treatment of type 2 diabetes mellitus.

Vutiglabridin is a synthetic structural analog of glabridin for the treatment of obesity.

Nrf2 activator-1 is a potent activator of NF-E2 related factor 2 (Nrf2). Nrf2 activator-1 has the potential for the treatment of COPD and other respiratory diseases, including asthma, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS) and pulmonary fibrosis (extracted from patent WO2018109647A1).

IRE1α kinase-IN-6 is a potent IRE1α inhibitor with an IC50 value of 4.4 nM.

Naphthofluorescein inhibits the interaction between HIF-1 and Mint3. Naphthofluorescein suppresses Mint3-dependent HIF-1 activity and glycolysis in cancer cells and macrophages without cytotoxicity in vitro and adverse effect in vivo. Naphthofluorescein is also a fluorescent pH-sensitive probe that can be used for functional Cerenkov imaging.

Izilendustat (hydrochloride) is a potent inhibitor of prolyl hydroxylase which stabilizes hypoxia inducible factor- 1 alpha (HIF- lα), as well as hypoxia inducible factor-2 (HIF-2). Izilendustat (hydrochloride) has the potential for the research of HIF- lα related diseases including Peripheral Vascular Disease (PVD), Coronary Artery Disease (CAD), heart failure, ischemia, anemia, colitis, and other inflammatory bowel diseases (extracted from patent WO2011057115A1/WO2011057112A1/WO2011057121A1).

eIF4E-IN-2 is a potent inhibitor of eukaryotic initiation factor 4e (eIF4e). eIF4E-IN-2 has the potential for researching eIF4e dependent diseases, including the research of cancer (extracted from patent WO2021003157A1, compound 1188).

eIF4E-IN-1 is a potent inhibitor of eIF4E. eIF4E-IN-1 inhibits immunosuppression components such as immune checkpoint proteins PD-1, PD-L1, LAG3, TIM3, and/or IDO, in order to inhibit or release immune suppression in certain diseases, such as cancer and infectious disease (extracted from patent WO2021003194A1, compound Y).